Key Takeaways
- Lenz Therapeutics has granted Arrotex exclusive rights to register and commercialize Vizz for presbyopia in Australia and New Zealand
- Under the agreement, Lenz will receive an upfront payment and a share of gross margin from product sales, while Arrotex will lead commercialization in the region
- The partnership is Lenz's fifth commercialization agreement outside the United States
Lenz Therapeutics has entered into an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals to register and commercialize Vizz (aceclidine ophthalmic solution 1.44%) for the treatment of presbyopia in Australia and New Zealand.
Under the agreement, Arrotex will receive exclusive commercialization rights for Vizz in the two markets, while Lenz Therapeutics will receive an upfront payment and a share of the gross margin generated from product sales. Financial terms were not disclosed.
Vizz is the first FDA-approved aceclidine-based eye drop indicated for the treatment of presbyopia.
"We are pleased to expand our global commercial partnership network for Vizz into Australia and New Zealand. Arrotex represents our fifth ex-US commercialization partnership for Vizz, underscoring our commitment to broadening access to our transformative presbyopia therapy worldwide," said Eef Schimmelpennink, president and chief executive officer of Lenz Therapeutics.
Mr. Schimmelpennink said Arrotex's commercial infrastructure and pharmacy network made it a strong partner for introducing the therapy in the region.
The announcement follows the FDA approval of Vizz in July 2025 for the treatment of presbyopia. The product has been commercially available in the United States since October 2025.
